Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate.

Hu L, Chen M, Chen X, Zhao C, Fang Z, Wang H, Dai H. · 2020

Read Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. by Hu L, Chen M, Chen X, Zhao C, Fang Z, Wang H, Dai H. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7181755.txt.

Introduction

Hu and co-authors trace how chemotherapy triggers a fiery form of cell death called pyroptosis. Their study appeared in Cell Death & Disease. Many cancer drugs kill through the BAK and BAX proteins in mitochondria. These proteins open the mitochondrial membrane and start a caspase cascade. A protein named GSDME decides which kind of death follows.

When caspase-3 cuts GSDME, cells die by pyroptosis instead of quiet apoptosis. The team showed this pathway at work with several drug treatments. Knocking down GSDME blocked the pyroptotic death. They also found a fat-based tag on GSDME that controls the process. A compound called 2-bromopalmitate, which blocks that tagging, reduced the death. The findings may help tune how cancer drugs kill.

Catalog record

CREATORHu L, Chen M, Chen X, Zhao C, Fang Z, Wang H, Dai H.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7181755

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate By Lei Hu, Meng Chen, Xueran Chen, Chenggang Zhao, Zhiyou Fang, Hongzhi Wang, Haiming Dai Published in: Cell Death & Disease DOI: 10.1038/s41419-020-2476-2 ABSTRACT Abstract Many chemotherapy treatments induce apoptosis or pyroptosis through BAK/BAX-dependent mitochondrial pathway. BAK/BAX activation causes the mitochondrial outer membrane permeabilization (MOMP), which induces the activation of pro-apoptotic caspase cascade. GSDME cleavage by the pro-apoptotic caspases determines whether chemotherapy drug treatments induce apoptosis or pyroptosis, however, its regulation mechanisms are not clear. In this study, we showed that TNFα+CHX and navitoclax-induced cancer cell pyroptosis through a BAK/BAX-caspase-3-GSDME signaling pathway. GSDME knockdown inhibited the pyroptosis, suggesting the essential role of GSDME in this process. Interestingly, GSDME was found to be palmitoylated on its C-terminal (GSDME-C) during chemotherapy-induced pyroptosis, while 2-bromopalmitate (2-BP) could inhibit the GSDME-C palmitoylation and chemotherapy-induced pyroptosis. Mutation of palmitoylation sites on GSDME also diminished the pyroptosis induced by chemotherapy drugs. Moreover, 2-BP treatment increased the interaction between GSDME-C and GSDME-N, providing a potential mechanism of this function. Further studies indicated several ZDHHC proteins including ZDHHC-2,7,11,15 could interact with and palmitoylate GSDME. Our findings offered new targets to achieve the transformation between chemotherapy-induced pyroptosis and apoptosis. Subject terms: Cell death, Cell signalling INTRODUCTION Pyroptosis is a newly identified programmed cell death (PCD), characterized by cell swelling, forming large bubbles on the plasma membrane and disruption of plasma membrane1. Originally regarded as an innate immune mechanism that occurs in macrophages, monocytes, dendritic cells (DCs), and T cells upon the stimulations by pathogens or the products from pathogens2,3, pyroptosis was found to be mediated by the pro-inflammatory caspases4,5. More recently, pyroptosis was also found to be mediated by pro-apoptotic caspases in cancer cells and human primary cells after induced by chemotherapies6,7. As a pro-inflammatory form of PCD, pyroptosis can protect multicellular organisms from invading pathogenic bacteria and microbial infections. However, its overactivation will lead to sepsis and lethal septic shock8. Pro-inflammatory caspases that induce pyroptosis include caspase-1 in both human and mice, caspase-4 and -5 in human, and caspase-11 in mice. Caspase-1 mediated pyroptosis is often activated by cannonical inflammasomes9, while caspase-4/5/11 mediated pyroptosis is often activated within non-canonical inflammasomes10. Pyroptosis can also be induced by pro-apoptotic caspases, such as caspase-36,7 and caspase-811,12. Caspase-3 is often activated by the death receptor mediated apoptotic pathway through the activation of caspase-8 or the mitochondrial apoptotic pathway through the activation of caspase-913. Many anti-cancer drugs induced cancer cell death through the mitochondrial pathway, which was controlled by BCL2 family proteins. Two BCL2 family members, BAK and BAX can form pores on the mitochondrial outer membrane (MOM) after activation, resulting in the release of mitochondrial inter-membrane components, which will cause the activation of caspase cascade14–16. The cleavage of gasdermin family proteins GSDMD and GSDME mediate pyroptotic characteristics. GSDMD is cleaved by activated pro-inflammatory caspases after Asp275 (Asp276 in mouse), generating an N-terminal domain (GSDMD-N)17–19. Originally defined as a putative oncosuppressor protein20, GSDME, is cleaved by caspase-3 after Asp270 generating an N-terminal GSDME (GSDME-N) upon the treatment of anti-cancer agents6,7,21. Both GSDMD-N and GSDME-N oligomerize and form large pores on the plasma membrane to induce plama membrane disruption, leading to the release of cellular contents, including pro-inflammatory mediators, and alamins. While caspase-3 is a pro-apoptotic caspase, the cleavage of GSDME by activated caspase-3 after chemotherapy drug treatments provides a cross-talk between the pro-infammatory pryroptosis and anti-inflammatory apoptosis. GSDME expression levels vary in different cell types and tissues. High levels of GSDME lead to pyroptosis while cells with low levels undergo apoptosis upon chemotherapy treatments9. In the presence of GSDME, chemotherapy drug-induced caspase-3 activation often leads to a pyroptotic characteristics6,7, because pyroptosis progresses faster than apoptosis18. Although GSDME cleaved by pro-apoptotic caspases convert apoptosis to pyroptosis, however, its regulation mechanisms are not clear. As one of the most common posttranslational modifications of proteins, palmitoylation is defined by the addition of saturated 16-carbon palmitic acid to specific cysteine residues22 and plays an important role in multiple intracellular physiological processes23–26. 2-BP is one of the most commonly used palmitoylation inhibitors, which can directly and irreversibly inhibit the palmitoyltransferase activity of all DHHC (Asp-His-His-Cys) proteins27. In this study, we not only found that chemotherapy-induced pyroptosis was mediated by the BAK/BAX-caspase-3-GSDME pathway, but also showed either BAK or BAX alone can mediate this process. More importantly, we found that GSDME was palmitoylated during chemotherapy-induced pyroptosis, while 2-BP could inhibit this process. RESULTS BAK and BAX enable TNFα+CHX and navitoclax to induce pyroptosis Previous studies have shown chemotherapy drugs induce pyroptosis through the GSDME cleavage6,7, while bacteria or LPS induces pyroptosis through GSDMD cleavage17–19. Many cancer cells do not express GSDME due to its promoter methylation28–30. We first screened several cancer cell lines for the expression of GSDMD and GSDME (Fig. 1a and Supplementary Fig. 1a). The colorectal cancer cell line HCT116 was chosen because it expresses high levels of GSDME but not GSDMD (Fig. 1a). [Figure: BAK/BAX deletion inhibits TNFα+CHX or navitoclax-induced pyroptosis.a Expresssion level of GSDMD and GSDME in various cell lines. b Expression of BAK/BAX in wild type (WT) and BAK/BAX double knockout (DKO) HCT116 cells. c, d At the indicated time points, the percentage of LDH release in the culture supernatants from HCT116 WT and DKO was measured after TNFα+CHX (c) or navitoclax (d) treatment. Error bars in this and subsequent figures: mean ± SD of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. e, f At the indicated time points, immunoblottings of GSDME, caspases, and cleaved caspases were performed in HCT116 WT and DKO cells treated with TNFα+CHX (e) or navitoclax (f). g, h After HCT116 WT and DKO cells were treated with TNFα+CHX (g) or navitoclax (h) for indicated time, representative microscopic images were taken. Scale bar in this and subsequent figures, 100 μm. i, j After TNFα+CHX (i) or navitoclax (j) treatment, HCT116 cells were collected at the indicated time points and stained with FITC-Annexin V and PI. The percentages of single PI positive, single FITC-Annexin V positive, and FITC-Annexin V/PI double positive HCT116 (WT or DKO) were detected by flow cytometry.] Many anti-cancer drugs induce apoptosis through the BAK/BAX-dependent apoptosis pathway31,32, however, whether this pyroptosis was dependent on BAK/BAX is not clear. To study this, wild type (WT) and BAK−/−BAX−/− (DKO) HCT116 cells (Fig. 1b) were first treated with navitoclax, the BCL2, BCLxL, and BCLw inhibitor33,34. After HCT116 cells were exposed to navitoclax (Supplementary Fig. 1b–d), we found navitoclax induced a concentration-dependent GSDME cleavage and also caspase-3, 7, and 9 cleavages (Supplementary Fig. 1b). Consistent with these observations, we observed the LDH release in WT HCT116 cells (Supplementary Fig. 1c) and pyroptotic morphologies, indicated by cell swelling and accompanied by large bubbles blown from the plasma membrane (Supplementary Fig. 1d). These observations together confirmed pyroptosis was induced in WT HCT116 cells upon navitoclax treatment. A time-course study of HCT116 cells treated with TNFα+CHX and navitoclax was further performed (Fig. 1 and Supplementary Fig. 2). Both treatments induced a time-dependent pyrotosis in WT HCT116 cells, as indicated by the LDH release (Fig. 1c, d), the cleavage of GSDME (Fig. 1e, f), the observation of pyroptotic cell morphologies (Fig. 1g, h) and the increased percentages of Annexin V+

Read the complete text